➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Harvard Business School
Dow
Baxter

Last Updated: October 20, 2021

DrugPatentWatch Database Preview

Meprobamate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

What are the generic sources for meprobamate and what is the scope of patent protection?

Meprobamate is the generic ingredient in nine branded drugs marketed by Medpointe Pharm Hlc, Wyeth Ayerst, Ferndale Labs, Alra, Teva, Acella, Alembic Pharms Ltd, Barr, Elkins Sinn, Heather, Impax Labs, Invagen Pharms, Ivax Sub Teva Pharms, Lannett, Lederle, Lee Km, Mallard, Mk Labs, Mylan, Nexgen Pharma Inc, Parke Davis, Perrigo, Pharmavite, Purepac Pharm, Pvt Form, Rising, Roxane, Sandoz, Scherer Labs, Solvay, Stanlabs Pharm, Sun Pharm Industries, Tablicaps, Taro, Usl Pharma, Valeant Pharm Intl, Vangard, Watson Labs, West Ward, Whiteworth Town Plsn, and Halsey, and is included in fifty-seven NDAs. Additional information is available in the individual branded drug profile pages.

There are twenty-two drug master file entries for meprobamate. Four suppliers are listed for this compound.

Summary for meprobamate
Drug Prices for meprobamate

See drug prices for meprobamate

Medical Subject Heading (MeSH) Categories for meprobamate
Anatomical Therapeutic Chemical (ATC) Classes for meprobamate

US Patents and Regulatory Information for meprobamate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Elkins Sinn MEPROBAMATE meprobamate TABLET;ORAL 015426-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Stanlabs Pharm MEPROBAMATE meprobamate TABLET;ORAL 014474-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Purepac Pharm MEPROBAMATE meprobamate TABLET;ORAL 084804-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Taro MEPROBAMATE meprobamate TABLET;ORAL 200998-002 May 23, 2011 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Medpointe Pharm Hlc MILTOWN meprobamate TABLET;ORAL 009698-002 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Alembic Pharms Ltd MEPROBAMATE meprobamate TABLET;ORAL 090122-002 Feb 18, 2009 AA RX No Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
McKinsey
Harvard Business School
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.